MedTrace Logo

Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)

NCT02235844 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-09-16

No results posted yet for this study

Summary

This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD). The potential muscle regenerative and anti-inflammatory properties of UC MSCs position them as a possible treatment option for DMD. Both of these properties could lead to potential benefits for a DMD patient.

Conditions

  • Duchenne's Muscular Dystrophy

Interventions

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cells

Sponsors & Collaborators

  • Aidan Foundation

    collaborator UNKNOWN

  • Neil H. Riordan PhD

    collaborator UNKNOWN

  • Allergy and Asthma Consultants, Wichita, Kansas

    lead OTHER

Principal Investigators

  • Maurice HV Strickland, MD · Allergy and Asthma Consultants of Wichita, KS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
28 Years
Max Age
31 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-09-30
Completion
2017-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02235844 on ClinicalTrials.gov